Expands access to much-needed iron therapy for millions of US patients Builds Sandoz portfolio of high-quality injectable iron therapies and sets stage for future launches Strengthens US supply of ...
Panelists discuss how chronic kidney disease leads to iron deficiency anemia through a complex interplay of impaired iron absorption, increased hepcidin production driven by inflammatory cytokines, ...
On Monday, the U.S. Food and Drug Administration (FDA) approved Amphastar Pharmaceuticals, Inc.’s (NASDAQ:AMPH) Abbreviated New Drug Application (ANDA) for Iron Sucrose Injection, USP 50mg/2.5mL, ...
According to the FDA, Amphastar's iron sucrose injection meets the criteria for bioequivalence and therapeutic equivalence to Venofer ® for the treatment of iron deficiency anemia in patients with ...
More than 6 million U.S. adults — most over the age of 60 — are living with heart failure.¹If you or someone you care about has heart failure, you may already know it’s a chronic but manageable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results